Abstract
Patent expiries, tightening healthcare budgets and a stricter regulatory
climate in the aftermath of the Vioxx withdrawal presented major challenges to
the pharmaceutical industry in 2006. These tougher operating conditions may
partly explain why companies that are less reliant on pharmaceuticals seem to
have performed so well last year. Johnson & Johnson, which only has 43% of its
revenue coming from pharmaceuticals, for example, toppled Pfizer from its
position at the top of the total revenue table for 2006.
The tough operating conditions can also be seen reflected in the general wave
of industry restructuring among generics and speciality pharma companies.
Among the generics players, consolidation changed the landscape quite
dramatically last year with Watson Pharmaceuticals acquiring Andrx to become
the third largest player in the US market, Barr Pharmaceuticals (formerly
known as Barr Laboratories) acquiring the Croatian firm Pliva, and a number of
smaller acquisitions by Indian companies, Dr Reddy' s and Ranbaxy Laboratories.
A similar story can be seen in Europe. In Germany, for example, Bayer beat
Merck KGaA to acquire Schering AG. Merck KGaA, meanwhile, went on to absorb
Europe' s largest biotech company, Serono, into its business. Other European
deals included Danish Nycomed' s surprise acquisition of Altana Pharma at the
very end of the year, and the purchase by Belgium' s UCB of Schwarz Pharma.
Biotech companies also saw considerable movement with, among other deals,
Crucell acquiring Berna Biotech for $476 million and Genzyme acquiring Anormed
for $584 million.
Mergers among the top players are rare these days, if only because there are
so few potential partners. There was one major acquisition in 2006 (when
Schering AG became part of Bayer) although in Japan, traditionally so averse
to mergers, Dainippon Sumitomo Pharma was created from Dainippon
Pharmaceutical and Sumitomo Pharmaceuticals at the very end of 2005.
A fair number of interesting smaller companies were bought by the larger
players in a bid to replenish their pipelines. Last year saw Pfizer buy
Powdermed and Rinat Neuroscience, for example. Merck & Co acquired Abmaxis,
Glycofi and Sirna Therapeutics; Astrazeneca bought Cambridge Antibody
Technology; Novartis bought Neutec Pharma; Abbott Laboratories acquired Kos
Pharmaceuticals, and Lilly extended its long-standing research partnership
with Icos by bringing it into the fold.
Table of Contents
CHAPTER 1 METHODOLGY AND DEFINITIONS
- 1.1 What are Scrip' s Pharmaceutical Company League Tables?
- 1.2 How is the data collected?
CHAPTER 2 LEADING COMPANIES RANKED BY TOTAL REVENUE
CHAPTER 3 LEADING COMPANIES RANKED BY GROWTH IN TOTAL REVENUE
CHAPTER 4 LEADING COMPANIES RANKED BY TOTAL SALES
CHAPTER 5 LEADING COMPANIES RANKED BY PHARMACEUTICAL SALES
CHAPTER 6 LEADING COMPANIES RANKED BY SHARE OF THE PHARMACEUTICAL MARKET
CHAPTER 7 LEADING COMPANIES RANKED BY TOTAL OPERTAING PROFIT
CHAPTER 8 LEADING COMPANIES RANKED BY TOTAL OPERATING PROFIT MARGIN
CHAPTER 9 LEADING COMPANIES RANKED BY NET PROFIT
CHAPTER 10 LEADING COMPANIES RANKED BY EARNINGS PER SHARE
CHAPTER 11 LEADING COMPANIES RANKED BY INCOME PER EMPLOYEE
CHAPTER 12 LEADING COMPANIES RANKED BY PHARMACEUTICAL OPERATING PROFIT
CHAPTER 13 LEADING COMPANIES RANKED BY PHARMACEUTICAL OPERATING PROFIT MARGIN
CHAPTER 14 LEADING COMPANIES RANKED BY TOTAL R&D EXPENDITURE
CHAPTER 15 LEADING COMPANIES RANKED BY TOTAL R&D EXPENDITURE AS
- A PERCENTAGE OF TOTAL SALES
- 15.1 Commentary
CHAPTER 16 LEADING COMPANIES RANKED BY TOTAL R&D EXPENDITURE AS A PERCENTAGE OF TOTAL REVENUE
CHAPTER 17 LEADING COMPANIES RANKED BY PHARMACEUTICAL R&D EXPENDITURE
CHAPTER 18 LEADING COMPANIES RANKED BY TOTAL CAPITAL EXPENDITURE
CHAPTER 19 LEADING COMPANIES RANKED BY SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
CHAPTER 20 LEADING COMPANIES RANKED BY TOTAL ASSETS
CHAPTER 21 LEADING COMPANIES RANKED BY CURRENT ASSETS
CHAPTER 22 LEADING COMPANIES RANKED BY WORKING CAPITAL
CHAPTER 23 LEADING COMPANIES RANKED BY PHARMACEUTICAL ASSETS
CHAPTER 24 LEADING BIOTECHNOLOGY COMPANIES RANKED BY TOTAL REVENUE
CHAPTER 25 LEADING BIOTECHNOLOGY COMPANIES RANKED BY R&D EXPENDITURE
CHAPTER 26 LEADING BIOTECHNOLOGY COMPANIES RANKED BY R&D EXPENDITURE AS A PERCENTAGE OF TOTAL REVENUE
APPENDIX 1 EXCHANGE RATES 2005 AND 2006
APPENDIX 2 MERGERS & ACQUISITIONS OF NOTE
LIST OF TABLES
- Table 2.1 Leading Companies Ranked by Total Revenue
- Table 3.1 Leading Companies Ranked by Growth in Total Revenue
- Table 4.1 Leading Companies Ranked by Total Sales
- Table 5.1 Leading Companies Ranked by Pharmaceutical Sales
- Table 6.1 Leading Companies Ranked by Share of the Pharmaceutical Market
- Table 7.1 Leading Companies Ranked by Total Operating Profit
- Table 8.1 Leading Companies Ranked by Total Operating Profit Margin
- Table 9.1 Leading Companies Ranked by Net Profit
- Table 10.1 Leading Companies Ranked by Earnings per Share
- Table 11.1 Leading Companies Ranked by Income per Employee
- Table 12.1 Leading Companies Ranked by Pharmaceutical Operating Profit
- Table 13.1 Leading Companies Ranked by Pharmaceutical Operating Profit
Margin
- Table 14.1 Leading Companies Ranked by Total R&D Expenditure
- Table 15.1 Leading Companies Ranked by Total R&D Expenditure as a
Percentage of Total Sales
- Table 16.1 Leading Companies Ranked by Total R&D Expenditure as a
Percentage of Total Revenue
- Table 17.1 Leading Companies Ranked by Pharmaceutical R&D Expenditure
- Table 18.1 Leading Companies Ranked by Total Capital Expenditure
- Table 19.1 Leading Companies Ranked by Selling, General and Administrative
(SG&A) Expenses
- Table 20.1 Leading Companies Ranked by Total Assets
- Table 21.1 Leading Companies Ranked by Current Assets
- Table 22.1 Leading Companies Ranked by Working Capital
- Table 23.1 Leading Companies Ranked by Pharmaceutical Assets
- Table 24.1 Leading Biotechnology Companies Ranked by Total Revenue
- Table 25.1 Leading Biotechnology Companies Ranked by R&D Expenditure
- Table 26.1 Leading Biotechnology Companies Ranked by R&D Expenditure as a
Percentage of Total Revenue
| 
